Skip to main content
. Author manuscript; available in PMC: 2021 Jan 23.
Published in final edited form as: Cancer Chemother Pharmacol. 2019 Sep 23;84(6):1289–1301. doi: 10.1007/s00280-019-03960-w

Figure 1. Study schema:

Figure 1.

carboplatin and paclitaxel alone were administered on day 1 of the first 21-day cycle. Veliparib was administered PO twice daily on days 1–7, and chemotherapy administered IV on day 3 of the second and subsequent cycles. Study agents were administered over a 21-day cycle. Paclitaxel and carboplatin were administered intravenously (day 1 of lead-in cycle 1 and day 3 of subsequent cycles with veliparib. Oral veliparib was administered twice daily on days 1–7 of each cycle, except for lead in cycle 1 for the first 46 patients